NSE · DRAGARWQ
Dr. Agarwal'S Eye Hosp Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹477 Cr with net profit ₹70 Cr — a 14.71% net margin, versus 13.59% the period before.
Shareholding
As of 2026-09-30
- Promoter72.67%
- Public22.57%
- FII2.22%
- DII2.54%
21,392 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.32× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #25 of 86 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,16,998 Cr | 55.61 | 12.34 | 20.48% | 7.91% |
| Manipal Health Enterpri Limited | ₹84,612 Cr | 90.22 | 5.15 | 10.59% | 7.81% |
| Max Healthcare Institute Ltd. | ₹82,877 Cr | 55.36 | 7.71 | 13.42% | 16.73% |
| Aster DM Quality Care Ltd. | ₹58,372 Cr | 150.48 | 13.88 | 8.48% | 6.54% |
| Fortis Healthcare Ltd. | ₹57,339 Cr | 53.75 | 5.79 | 10.53% | 11.02% |
| Narayana Hrudayalaya Ltd. | ₹35,213 Cr | 40.85 | 7.76 | 17.76% | 9% |
| Global Health Limited | ₹34,497 Cr | 60.26 | 8.71 | 14.05% | 11.88% |
| Dr. Lal Path Labs Ltd. | ₹32,266 Cr | 57.36 | 12.86 | 20.13% | 18.75% |
| Krishna Institute of Medical Sciences Ltd. | ₹29,594 Cr | 141.77 | 7.9 | 10.74% | 4.85% |
| Molbio Diagnostics Ltd. | ₹15,128 Cr | 90.47 | 11.05 | 14.25% | 11.78% |
| Dr. Agarwal'S Eye Hosp Limited(this company) | ₹2,471 Cr | 32.41 | 7.13 | 20.24% | 15.34% |
AI analysis
AI-generated · google/gemini-2.5-flashDr. Agarwal'S Eye Hosp Limited, operating in the Healthcare sector, has a market capitalization of Rs 2422 Cr. The company's EPS stands at Rs 145.05. Its book value is Rs 716.56, with a dividend yield of 8%. The 52-week high for the share price was Rs 6059.7 and the 52-week low was Rs 4600.
Positives
- +Annual revenue increased from Rs 140.62 Cr in Mar 2021 to Rs 402.24 Cr in Mar 2025.
- +Net profit improved from a loss of Rs 1.44 Cr in Mar 2021 to a profit of Rs 54.65 Cr in Mar 2025.
- +Return on Equity (ROE) is 20.24% and Return on Capital Employed (ROCE) is 15.63%.
- +Diluted EPS increased to Rs 116.28 in Mar 2025 from a negative Rs 3.06 in Mar 2021.
Negatives
- −The debt-to-equity ratio is 1.64, which is relatively high.
- −Promoter share pledge stands at 7.67% as of June 30, 2026.
- −Quarterly EPS data is not available for any of the reported periods.
- −DII and FII holdings decreased to 2.05% and 2.24% respectively as of June 30, 2026, from unspecified levels in earlier periods.
Financial Performance
The company's annual revenue has shown growth over the past few years. Revenue increased from Rs 140.62 Cr in Mar 2021 to Rs 402.24 Cr in Mar 2025. Net profit also grew from a loss of Rs 1.44 Cr in Mar 2021 to a profit of Rs 54.65 Cr in Mar 2025. Diluted EPS rose from a negative Rs 3.06 in Mar 2021 to Rs 116.28 in Mar 2025.
Profitability & Returns
Dr. Agarwal's Eye Hosp Limited reported a profit margin of 14.89%. The company's Return on Equity (ROE) was 20.24% and Return on Capital Employed (ROCE) was 15.63%. Over the years, the EBITDA has grown from Rs 12.08 Cr in Mar 2021 to Rs 84.14 Cr in Mar 2025.
Balance Sheet
The company has a debt-to-equity ratio of 1.64. The book value per share is Rs 716.56. Further detailed breakdowns of assets and liabilities are not available in the provided data.
Ownership & Pledges
As of June 30, 2026, promoters held 72.67% of the shares. Public shareholding was 23.04%, while institutions held 4.29%. Foreign Institutional Investors (FIIs) held 2.24% and Domestic Institutional Investors (DIIs) held 2.05%. A total of 7.67% of promoter shares were pledged as of the same date.
Regulatory & Surveillance
No information regarding the company's status on any surveillance list was provided in the available data. The company's shareholding data for the period June 30, 2026 indicates a pledge of 7.67% of promoter shares.
Data as of — price: 2026-10-28 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Dr. Agarwal'S Eye Hosp Limitedshare price & fundamentals